ORPHA:668
Osteosarcoma
Also known as: Osteogenic sarcoma
Publications
131,795
99.9th percentile
Trials
319
Interventional, condition-specific
Researchers
1,255
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Osteosarcoma is a primary malignant tumour of the skeleton characterised by the direct formation of immature bone or osteoid tissue by the tumour cells.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0002629
- OMIM:259500
- UMLS:C0585442
- NCIT:C53707
Additional Mondo synonyms (4)
bone osteosarcoma · osteosarcoma of bone · osteosarcoma, somatic · osteosarcoma, somatic mutation
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
131,795 matched papers (77,093 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
319 matched on ClinicalTrials.gov (73 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
131,795
131,795 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
131,795 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
77,093 in the last 10 years · medium confidence · 99.9th percentile (publications denominator)
Phrase hits: 131,795 · MeSH hits: 0
Who's working on it?
1,255
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Chen X9 papers · 2026
Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Papers in Europe PMC - 02Zhang Y9 papers · 2026
Department of Orthopedic, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Papers in Europe PMC - 03Li J8 papers · 2026
Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Papers in Europe PMC - 04Wang J8 papers · 2026
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China.
Papers in Europe PMC - 05Wang Y7 papers · 2026
Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing, China.
Papers in Europe PMC - 06Liu J6 papers · 2026
Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
Papers in Europe PMC - 07Li Z5 papers · 2026
Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 Wenhuaxi Road, Jinan, Shandong Province 250012, China.
Papers in Europe PMC - 08Liu Y5 papers · 2026
Department of Thoracic Surgery/Bone and Soft Tissue Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430079, Hubei, China.
Papers in Europe PMC - 09Zhang Z5 papers · 2026
Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
Papers in Europe PMC - 10Li H4 papers · 2026
Institute of Biomedical Sciences Shandong Provincial Key Laboratory of Animal Resistance Biology Collaborative Innovation Center of Cell Biology in Universities of Shandong Center For Cell Structure and Function College of Life Sciences Shandong Normal University Jinan China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
319
interventional trials for this specific condition
319 interventional trials matched this specific condition name; 73 currently recruiting in our sample.
Data as of 27 July 2026
319 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 99.6th percentile).
medium confidence · 99.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
319 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07479732·RECRUITING·Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
Conditions: Osteosarcoma · Osteosarcoma Metastatic·Matched via name phrase
- NCT07142863·NOT YET RECRUITING·Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients
Conditions: Osteosarcoma · Neoadjuvant Therapy · Neoadjuvant Chemotherapy · PD-L1 Antibody·Matched via name phrase
- NCT07052383·RECRUITING·Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas
Conditions: Osteosarcoma · Soft Tissue Sarcoma·Matched via name phrase
- NCT04698785·RECRUITING·Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
Conditions: Bone Sarcoma · Osteosarcoma·Matched via name phrase
- NCT05182164·RECRUITING·Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
Conditions: Soft Tissue Sarcoma Adult · Advanced Soft-tissue Sarcoma · Ewing Sarcoma · Osteosarcoma·Matched via name phrase
- NCT04758000·RECRUITING·Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse
Conditions: Osteosarcoma · Ewing Sarcoma·Matched via name phrase
- NCT04282044·RECRUITING·Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Conditions: Solid Tumor, Adult · Triple Negative Breast Cancer · Colorectal Cancer · Hepatocellular Carcinoma·Matched via name phrase
- NCT07321912·RECRUITING·Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Conditions: Osteosarcoma · Ewing Sarcoma·Matched via name phrase
- NCT07560826·NOT YET RECRUITING·The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma
Conditions: Osteosarcoma in Children · Osteosarcoma in Adolescents and Young Adults·Matched via name phrase
- NCT04851119·RECRUITING·Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Conditions: Colorectal Carcinoma · Endometrial Carcinoma · Melanoma · Neuroblastoma·Matched via name phrase
- NCT06500819·RECRUITING·Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Conditions: Neuroblastoma · Sarcoma · Osteosarcoma·Matched via name phrase
- NCT07428993·RECRUITING·Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma
Conditions: Pediatric Osteosarcoma·Matched via name phrase
- NCT07211737·RECRUITING·NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
Conditions: Relapsed Neuroblastoma · Refractory Neuroblastoma · Relapsed Osteosarcoma · Refractory Osteosarcoma·Matched via name phrase
- NCT05588648·RECRUITING·Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
Conditions: Osteosarcoma·Matched via name phrase
- NCT06645808·RECRUITING·PET-imaging of Two Vartumabs in Patients With Solid Tumors
Conditions: Solid Tumor · Colon Carcinoma · Rectal Carcinoma · Osteosarcoma·Matched via name phrase
Observational and natural-history studies
80 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05779670·RECRUITING·Adherence to a Personalized Home Exercise Program in Patients With Bone Tumor Undergoing Lower Extremity Salvage Surgery
Conditions: Osteosarcoma · Ewing Sarcoma · Chondrosarcoma · Bone Tumor·Matched via name phrase
- NCT03442465·RECRUITING·Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
Conditions: Bone Sarcoma · Osteosarcoma · Chondrosarcoma · Ewing's Sarcoma·Matched via name phrase
- NCT04890067·RECRUITING·Observational Study in Localized Osteosarcoma
Conditions: Localized Osteosarcoma·Matched via name phrase
- NCT06017518·RECRUITING·An Observational Study of Local Relapse After High Grade Osteosarcoma
Conditions: Osteosarcoma·Matched via name phrase
- NCT00411060·RECRUITING·Clinical Orthopaedic Data Bank (Acute and Chronic)
Conditions: Osteoarthritis · Osteosarcoma · Scoliosis · Cerebral Palsy·Matched via name phrase
- NCT06064682·RECRUITING·An Organoid-based Functional Precision Medicine Trial in Osteosarcoma
Conditions: Osteosarcoma·Matched via name phrase
- NCT03458520·RECRUITING·Pediatric PET/MR Image Registry
Conditions: Soft Tissue · Lymphoma · Osteosarcoma·Matched via name phrase
- NCT06384404·RECRUITING·Upfront Surgical Resection for Osteosarcoma
Conditions: Osteosarcoma·Matched via name phrase
- NCT01790152·RECRUITING·Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Conditions: Hodgkin Lymphoma in Remission · Leukemia in Remission · Lymphoblastic Lymphoma · Osteosarcoma·Matched via name phrase
- NCT06776198·NOT YET RECRUITING·Precision Therapy Based on Immune Microenvironment by Transcriptome Sequencing of Osteosarcoma, a Prospective, Multi-cohort Exploratory Clinical Study
Conditions: Osteosarcoma · Transcriptome · Tumor Microenvironment · Precision Medicine·Matched via name phrase
- NCT05062707·RECRUITING·Early Ageing During Therapy in AYA Cancer Patients
Conditions: Cancer · Leukemia · Hodgkin Lymphoma · Testicular Cancer·Matched via name phrase
- NCT05535283·NOT YET RECRUITING·Assessing Clinical Trial Experiences of Patients With Osteosarcoma
Conditions: Osteosarcoma·Matched via name phrase
- NCT06935864·RECRUITING·Tissue Expression of Krüppel-Like Factors 4 and 7 in Bone Tumors
Conditions: Osteosarcoma in Children · Ewing Sarcoma of Bone or Soft Tissue·Matched via name phrase
- NCT04132895·RECRUITING·ICONIC: Improving Outcomes Through Collaboration in OsteosarComa
Conditions: Osteosarcoma·Matched via name phrase
- NCT06927596·NOT YET RECRUITING·A Look Back at How Well Interventional Treatments Work for Bronchopleural Fistulas in Patients With Lung Metastases From Osteosarcoma
Conditions: Osteosarcoma Metastatic·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Osteosarcoma" OR "Osteogenic sarcoma" OR "bone osteosarcoma" OR "osteosarcoma of bone" OR "osteosarcoma of the bone" OR "osteosarcoma, somatic" OR "osteosarcoma, somatic mutation"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Osteosarcoma" OR "Osteogenic sarcoma" OR "bone osteosarcoma" OR "osteosarcoma of bone" OR "osteosarcoma of the bone" OR "osteosarcoma, somatic" OR "osteosarcoma, somatic mutation"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 319 interventional · 80 observational · 3 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T14:49:59.724Z
